

2022-001067-27

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

W06 Ricerca farmaco

Titolo/oggetto del contratto di sperimentazione	A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Codice EUDRACT	2022-001067-27
Promotore	Bayer Spa
Codice del protocollo del promotore	20604 (BAY 2433334 Oceanic Stroke)
Data di nullaosta	06-02-2023
Data sottoscrizione del contratto	15-02-2023
Data di chiusura	
Budget	4.190,00
Rimborsi	0,00
Totale	4.190,00
note	
Data ultima modifica	02-03-2023 15:30:52

Principal investigators

Nome Unità Operativa Neurologia di Cesena

Nome principal investigator Marco Longoni

Principal investigator [Marco Longoni Neurologia di Cesena](#)

CV Principal investigator /documenti/W06/20231205/Longoni_Marco_CV.pdf
